Adocia Asset Resilience Ratio
Adocia asset resilience ratio. Adocia (ADOC) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ADOC days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Adocia (2016–2023)
Asset resilience ratio of Adocia from 2016 to 2023. This chart shows how Adocia's Asset Resilience Ratio has changed over time. Read Adocia (ADOC) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Adocia's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ADOC current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adocia maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adocia Industry Peers by Asset Resilience Ratio
Compare Adocia's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Adocia Asset Resilience Ratio by Year (2016–2023)
Adocia asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Adocia.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 16.10% | €4.02 Million ≈ $4.70 Million |
€24.96 Million ≈ $29.18 Million |
-40.80pp |
| 2022-12-31 | 56.91% | €17.42 Million ≈ $20.37 Million |
€30.61 Million ≈ $35.79 Million |
+6.46pp |
| 2021-12-31 | 50.45% | €15.16 Million ≈ $17.73 Million |
€30.05 Million ≈ $35.14 Million |
-11.80pp |
| 2020-12-31 | 62.25% | €28.11 Million ≈ $32.87 Million |
€45.17 Million ≈ $52.80 Million |
-8.23pp |
| 2019-12-31 | 70.47% | €43.66 Million ≈ $51.04 Million |
€61.95 Million ≈ $72.43 Million |
+13.59pp |
| 2018-12-31 | 56.88% | €39.84 Million ≈ $46.58 Million |
€70.04 Million ≈ $81.89 Million |
-7.81pp |
| 2017-12-31 | 64.69% | €34.78 Million ≈ $40.66 Million |
€53.76 Million ≈ $62.85 Million |
-8.96pp |
| 2016-12-31 | 73.65% | €58.04 Million ≈ $67.85 Million |
€78.80 Million ≈ $92.12 Million |
-- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more